

Supplemental Digital Content 2

Secondary objectives

Secondary objectives evaluated (i) immunogenicity of a single MenACWY-TT dose in terms of percentage of participants with rSBA-MenA, rSBA-MenC, rSBA-MenW, and rSBA-MenY antibody titres $\geq 1:8$, $\geq 1:128$ and geometric mean titres (GMTs) at 1 month post-vaccination; (ii) the percentage of participants with anti-tetanus toxoid concentrations ≥ 0.1 international unit/mL, and geometric mean concentrations at 1 month post-vaccination; (iii) antibody persistence induced by MenACWY-TT in terms of the percentage of participants with rSBA-MenA, rSBA-MenC, rSBA-MenW, and rSBA-MenY titres $\geq 1:8$, $\geq 1:128$ and GMTs, 2 years after MenACWY-TT vaccination; (iv) safety and reactogenicity of one dose of MenACWY-TT.